Open-Label, Phase 1 Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the maximum tolerated dose (MTD) or appropriate target dose if MTD not reached to identify the recommended phase 2 dose of LOR-253 HCl in patients with advanced or metastatic solid tumours.
8 weeks
Yes
Andrea Cercek, M.D.
Principal Investigator
Memorial Sloan-Kettering Cancer Center
United States: Food and Drug Administration
253-SOL1-01
NCT01281592
January 2011
June 2013
Name | Location |
---|---|
MD Anderson Cancer Center | Houston, Texas 77030-4096 |
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |